AAM comments on Amneal's U.S. expansion of end-to-end biosimilars development with their acquisition of Kashiv BioSciences
Adds Chicago research and development facility, New Jersey manufacturing site
AAM
The Biosimilars Council and AAM applaud senate markup and committee passage of the expedited access to Biosimilars Act
Legislation codifies FDA's science-based approach to biosimilar review by limiting comparative efficacy studies; Introduced and passed House Committee this week.
AAM, Biosimilars Council praise House action on biosimilar bills
Legislative progress codifies FDA's science-based approach to biosimilar review by limiting comparative efficacy studies; Eliminates arbitrary distinction between interchangeable biologics and biosimilars.
AAM praises Senate committee approval of biosimilar and patent reform bills
AAM thanked the Senate HELP Committee for advancing legislation and urged policymakers to focus on expanding patient access to affordable medicines.
AAM applauds 232 Investigation Executive Order on Pharmaceuticals
“This decision will help enhance the generic medicines supply chain."
AAM and Biosimilars Council praise FDA plan to simplify biosimilar development
FDA draft guidance removes redundant PK testing requirements where scientifically rigorous data already exists.
AAM highlights Board Chair Bob Hoffman in new profile
Hoffman emphasized what he called a return to fundamentals for the industry, highlighting disciplined execution, competition, and collaboration as key to long-term sustainability.
AAM’s John Murphy III testifies before Congress on lowering health care costs and the Rx drug supply chain
Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients.
Bob Hoffman named chair of the Association for Accessible Medicines Board of Directors
“It is an honor to serve as AAM board chair, and I thank the board for the privilege,” said Bob Hoffman.
Over 36 groups join the Biosimilars Council and AAM to reiterate support for interchangeability legislation
Call for passage of Biosimilar Red Tape Elimination Act.
2026 Health Care Outlook: John Murphy III, AAM
By John Murphy III, president and CEO of the Association for Accessible Medicines
AAM applauds Q1/Q2 House bill passage
Cuts red tape, brings patient faster access to lower-cost medicines.
AAM and the Biosimilars Council praise FDA announcement on biosimilars clinical efficacy studies and interchangeability
FDA Commissioner Makary joined AAM’s GRx+Biosims 2025 conference today.
AAM requests federal injunction to block Connecticut’s unconstitutional drug price law
Generic pharmaceutical trade group steps in to protect patient access to affordable generic drugs.
AAM pushes back on Colorado drug price cap
AAM President John Murphy III noted that prices for generic and biosimilar medicines keep falling, yet no biosimilar for Enbrel is available in the U.S.
AAM praises Q1/Q2 House bill markup
The bipartisan, bicameral legislation was included in the 2024 year-end spending bill and reintroduced in this Congress.